文献速递乳腺MR

评估Node-RADS 1.0在乳腺癌腋窝淋巴结评估中的临床效用:与传统MRI诊断的比较

Evaluating the clinical utility of Node-RADS 1.0 for axillary lymph node assessment in breast cancer: comparison with conventional MRI diagnosis.
PubMed 文献 · Br J Radiol · 2026-01-01

这项回顾性研究纳入临床T1-T2期乳腺癌女性,比较Node-RADS 1.0评分与传统MRI诊断对腋窝淋巴结转移和病理腋窝淋巴结负荷的诊断性能。诊断腋窝淋巴结转移时Node-RADS >1为最佳截断值,敏感度低于传统MRI诊断(56% vs 71%,P < .01),特异度相当(92% vs 85%,P = .16)。

要点

  • 诊断腋窝淋巴结转移时Node-RADS >1为最佳截断值,敏感度56%、特异度92%。
  • 评估病理腋窝淋巴结负荷时Node-RADS >2为最佳截断值,敏感度55%、特异度82%。
  • Node-RADS <3的患者中,腋窝淋巴结转移者皮质形态和可疑患侧淋巴结征象存在显著差异。

核心结论

  • Node-RADS 1.0评估腋窝淋巴结转移的敏感度低于传统MRI诊断,但在评估腋窝淋巴结转移和病理腋窝淋巴结负荷时表现出良好的特异度。

研究设计与样本

  • 回顾性研究,纳入2014年4月至2023年3月期间接受手术的临床T1-T2期乳腺癌女性,先按常规临床诊断标准评估MRI腋窝淋巴结状态,间隔2周后基于术前MRI赋予Node-RADS评分,用约登指数确定最佳截断值。

关键影像表现/征象

  • 在Node-RADS <3的患者中,腋窝淋巴结转移者的皮质形态和可疑患侧淋巴结征象存在显著差异。

诊断标准与关键数值

  • 诊断腋窝淋巴结转移的最佳截断值为Node-RADS >1。
  • Node-RADS评分诊断腋窝淋巴结转移的敏感度为56%,传统MRI腋窝淋巴结状态为71%(P < .01)。
  • Node-RADS评分诊断腋窝淋巴结转移的特异度为92%,传统MRI腋窝淋巴结状态为85%(P = .16)。
  • 评估病理腋窝淋巴结负荷的最佳截断值为Node-RADS >2。
  • Node-RADS >2评估病理腋窝淋巴结负荷的敏感度为55%,传统MRI诊断标准为77%(P < .01);特异度为82%,传统MRI诊断标准为62%(P < .01)。

临床应用与阅片要点

  • Node-RADS 1.0诊断腋窝淋巴结转移的敏感度低于传统MRI诊断,阅片时需注意其可能漏诊。
  • Node-RADS 1.0在评估腋窝淋巴结转移和病理腋窝淋巴结负荷时特异度良好。
  • 作者认为皮质形态和可疑患侧淋巴结征象在提高Node-RADS 1.0敏感度方面的潜在价值需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the clinical utility of Node-Reporting and Data System (Node-RADS) 1.0 in assessing axillary lymph node (ALN) on breast MRI.

METHODS: This retrospective study included women with clinical T1-T2 stage breast cancer who underwent surgery between April 2014 and March 2023. MRI-ALN status was first evaluated using routine clinical diagnostic criteria. Node-RADS scores were subsequently assigned based on preoperative MRI after a 2-week interval. The optimal cut-off was determined using the Youden index. Diagnostic performance was compared for assessing ALN metastasis (ALNM) and pathological ALN (pALN) burden. In the secondary analysis, differences in imaging features were further evaluated in patients with Node-RADS < 3.

RESULTS: The optimal cut-off for diagnosing ALNM was Node-RADS >1. Compared with MRI-ALN status, Node-RADS score demonstrated lower sensitivity (56% vs. 71%, P < .01), but comparable specificity (92% vs. 85%, P = .16). For assessing pALN burden, Node-RADS > 2 was the optimal cut-off with lower sensitivity (55% vs. 77%, P < .01) but higher specificity (82% vs. 62%, P < .01). In the secondary analysis, patients with ALNM showed significant differences in cortical morphology and the suspicious breast-side lymph node sign.

CONCLUSIONS: Node-RADS 1.0 showed lower sensitivity than conventional MRI diagnosis in assessing ALNM but demonstrated good specificity in evaluating ALNM and pALN burden.

ADVANCES IN KNOWLEDGE: Node-RADS 1.0 showed lower sensitivity than conventional MRI diagnosis in assessing ALNM. The potential values of cortical morphology and the suspicious breast-side lymph node sign in improving the sensitivity of Node-RADS 1.0 warrant further investigation.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Liao J, Liu C, Huang X, et al. Evaluating the clinical utility of Node-RADS 1.0 for axillary lymph node assessment in breast cancer: comparison with conventional MRI diagnosis. Br J Radiol. 2026. PMID: 41352974. doi:10.1093/bjr/tqaf304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。